DATE: 5-28-03	APPL. S.N.: 091734,861
TO EXAMINER: S. Chundury	ART UNIT: _/637
MOSE MONTGOMERY ROOM HEIS	MAILROOM DATE 5-21-03
AFTER FINAL YES NO NUMBER OF T.D(S). FILED	
[4 The T.D. is PROPER and has been recorded. (See 14.23).	
[] The T.D. is NOT PROPER and has not been accepted for the reason(s) checked below. (See 14.24).	
[] The recording fee of \$ has not been submitted nor is there any pre authorization in the application file to charge to a deposit account. (See 14.26.07)	
[] Application Examiner has not processed T.D. fee. (See fee author	ization).
[] The T.D. does not satisfy Rule 321(b)(3) in that the person who has signed the T.D. has not stated his/her interest (and/or the extent of the interest of the business entity represented by the signature) in the application/patent. (See 14.26 and 14.26.01).	
[] The T.D. lacks the enforceable only during the common owership clause needed to overcome a double patenting rejection, Rule 321(c). (See 14.27, 14.27.01).	
[] It is directed to a particular claims(s), which is not acceptable since term of the entire patent to be granted. MPEP 1490. (See 14.26, 14.26.	the disclaimer must be of a terminal portion of the 02).
[] The person who signed the terminal disclaimer: [] has failed to state his/her capacity to sign for the business [] is not recognized as an officer of the assignee, (See 14.29)	entity, (See 14.28). and possibly 14.29.01).
[] No documentary evidence of a chain of title from the original inventor, and frame specified as to where such evidence is recorded in the office. 3 documentary evidence or the specifying of the reel and frame may be four applicant. (See 14.30).	(s) to assignee has been submitted, nor is the reel 67 CFR 3.73(b). (See 1140 O.G. 72). <u>NOTE:</u> This and in the T.D. <u>or</u> in a seperate paper <u>submitted by</u>
[] No "statement" specifying that the evidentiary documents have been reknowledge and belief the title is in the assignee seeking to take action. 37	reviewed and that, to the best of the assignee's CFR 3.73(b). (See 1140 O.G. 72) (See 14.31).
[] The T.D. is not signed. (See 14.26, 14.26.3). or 14.26.03 if TD is not	signed by all the owners.
[] Attorney not of record in oath/decl. or a seperate paper filed appointing	g a new or associate attorney. (See 14.29.01).
[] The serial number of the application (or the number of the patent) whice missing or incorrect. (See 14.32).	ch forms the basis for the double patenting is
[] The serial number of this application (or the number of the patent in record or incorrect. (See 14.26, 14.26.04 or 14.26.05).	exam or relssue case(s) being disclaimed is missing
[] The period disclaimed is incorrect or not specified. (See 14.27, 14.27.2	or 14.27.3)(For Samples 14.27.04 and 14.27.05)
[] Other:	
[] Suggestion to request refund of \$ (See 14.35, 14.36).	
[] EXAMINER NOTE: IF APPLICATION IS IN CONDITION FOR ALLOWANCE ANY OF THE ABOVE INFORMALTIES MAY BE FAXED IN TO THE GROUP	
FOR SAMPLE TERMINAL DISCLAIMERS AND CERTIFICATES:	
 Sample of a TD over a pending application and assignee Certificate (See 14.37). Sample of a TD over a prior patent and assignee Certificate (See 14.38). Sample Assignee Certificate under 37 CFR 3.73 (b) (See 14.39) 	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Roland Carlsson et al.

Serial No.: 09/734,801

Filed: December 12, 2000

For: "A METHOD FOR IN VITRO

MOLECULAR REVOLUTION OF

PROTEIN FUNCTION"

Examiner: CHUNDURU, S.

Art Unit: 1637

Response to Paper No. 16

TERMINAL DISCLAIMER RESPONSIVE TO OBVIOUSNESS-TYPE DOUBLE PATENTING REJECTION

The above-identified patent application (hereinafter "the '801 application") is owned by the BioInvent International AB, Sweden (hereinafter "Assignee").

Assignee, by its undersigned agent, who is agent of record in the '801 application, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the '801 application which would extend beyond the expiration date of the full statutory term, as defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of U.S. Patent No. 6,159,690, issued December 12, 2000 on U.S. Application No. 09/098,287, of which Assignee is the owner of all right, title and interest.

Assignee, by its undersigned agent, hereby agrees that any patent so granted on the '801 application shall be enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to said U.S. Patent No. 6,159,690, this agreement to run with any patent granted on the '801 application and to be binding upon the grantee, its successors or assigns.

In making the foregoing disclaimer, Assignee does not disclaim the terminal part of any patent granted on the '801 application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and

18

173 of U.S. Patent No. 6,159,690, as presently shortened by any terminal disclaimer filed prior to patent grant, in the event that U.S. Patent No. 6,159,690: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued or is in any manner terminated prior to expiration of its full statutory term as presently or subsequently shortened by any terminal disclaimer, as the case may be, except for the separation of legal title stated above.

A check for \$110.00 is enclosed herewith to cover the statutory disclaimer fee. The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 04-1406.

Respectfully submitted,

DANN, DORFMAN, HERRELL AND SKILLMAN A Professional Corporation

Kathleen D. Rigaut, Ph.D., PTO Registration No. 43,047

Telephone: (215) 563-4100